Literature DB >> 3493070

Immune reactivity in SL2 lymphoma-bearing mice compared with SL2-immunized mice.

R A De Weger, B Wilbrink, R M Moberts, D Mans, R Oskam, W Den Otter.   

Abstract

We have studied the rather paradoxical phenomenon of the growth of an antigenic tumor in an immunocomponent host. This phenomenon was studied by comparing the lymphocyte reactivity and the macrophage cytotoxicity, during SL2 growth in DBA/2 mice (SL2-bearing mice) and in DBA/2 mice immunized against SL2 tumor cells (SL2-immune mice). Immune mice rejected a challenge of tumor cells. The immune T-lymphocytes rendered macrophages cytotoxic (arming) and were able to transfer tumor resistance to naive animals. Nonimmunized mice did not reject a challenge of SL2 cells. In these tumor-bearing mice various forms of immune reactivity were tested. Lymphocytes with the capacity to arm macrophages could not be found in the lymphoid organs. However, lymphocytes isolated from the tissue directly surrounding the subcutaneous SL2 tumor could arm macrophages in vitro. Shortly after subcutaneous tumor grafting cytotoxic macrophages were found in the peritoneal cavity. In the serum macrophage arming factors were detected that rendered macrophages cytotoxic in vitro. This cytotoxicity of the peritoneal macrophages and the presence of macrophage arming factors in the serum showed a similar biphasic pattern. The first phase of cytotoxicity between day 3 and 8 after tumor grafting was tumor (SL2) specific. The second phase from day 12 and onwards was not tumor specific. During the first 4 days after SL2 grafting the DBA/2 mice expressed a specific concomitant immunity to a second tumor graft. Then 7 or more days after grafting the first SL2 tumor, the concomitant immunity was nonspecific as the growth of a second SL2 tumor graft and a L5178Y (DBA/2) tumor graft were inhibited. In addition, the immune suppressive activity of serum and lymphocytes was tested. Neither serum nor lymphocytes from SL2-bearing mice suppressed the macrophage arming capacity of SL2 immune lymphocytes. Lymphocytes from tumor-bearing mice did not inhibit the capacity of SL2-immune lymphocytes to transfer resistance to naive animals. On the contrary, lymphocytes obtained from SL2-bearing mice 14 days after SL2 grafting transfered tumor resistance in a Winn-type assay. These data suggest that the growth of an antigenic tumor is due to the inability of the immune system to mount an effective antitumor effector cell population during tumor growth, rather than an immune suppression of the antitumor reactivity, as a limited immune reactivity could be detected in tumor-bearing mice, whereas immune suppression could not be detected.

Entities:  

Mesh:

Year:  1987        PMID: 3493070     DOI: 10.1007/BF00199829

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  30 in total

1.  Delayed-type hypersensitivity: activation of mast cells by antigen-specific T-cell factors initiates the cascade of cellular interactions.

Authors:  P W Askenase; H Van Loverent
Journal:  Immunol Today       Date:  1983-09

2.  Mechanism of immunologically specific killing of tumour cells by macrophages.

Authors:  R Evans; P Alexander
Journal:  Nature       Date:  1972-03-24       Impact factor: 49.962

3.  Cytotoxicity by macrophages and monocytes.

Authors:  R A De Weger; B A Runhaar; W Den Otter
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

4.  Cell surface antigen phenotypes and enzyme expression patterns of two murine T-cell lymphomas derived from early and/or mature thymus cells.

Authors:  H F Dullens; J Hilgers; C D Van Basten; R A De Weger; E De Heer; W Den Otter
Journal:  Leuk Res       Date:  1982       Impact factor: 3.156

5.  Macrophages and resistance to tumours. I. Inhibition of delayed-type hypersensitivity reactions by tumour cells and by soluble prducts affecting macrophages.

Authors:  M Nelson; D S Nelson
Journal:  Immunology       Date:  1978-02       Impact factor: 7.397

6.  Macrophage-like cells as research tools in transfer experiments.

Authors:  H van Loveren; W den Otter
Journal:  Immunobiology       Date:  1983-02       Impact factor: 3.144

7.  Adoptive immunotherapy of intracerebral murine lymphomas: role of different lymphoid populations.

Authors:  L Romani; B Nardelli; R Bianchi; P Puccetti; M Mage; M C Fioretti
Journal:  Int J Cancer       Date:  1985-05-15       Impact factor: 7.396

8.  Immunologic responses to a murine mammary adenocarcinoma: in vitro production of specific killer cells is dependent on active T lymphocytes.

Authors:  Y Yamamura
Journal:  J Immunol       Date:  1978-01       Impact factor: 5.422

9.  The induction of lymphocytes with the capacity to render macrophages cytotoxic in an allogeneic murine system.

Authors:  R A De Weger; E Pels; W Den Otter
Journal:  Immunology       Date:  1982-11       Impact factor: 7.397

10.  Macrophages and lymphoid tissues in mice with concomitant tumour immunity.

Authors:  D S Nelson; R Kearney
Journal:  Br J Cancer       Date:  1976-09       Impact factor: 7.640

View more
  5 in total

1.  Initial immunochemical characterization of specific macrophage-arming factor.

Authors:  R A De Weger; R J Vandebriel; H Slager; D Mans; H Van Loveren; B Wilbrink; H F Dullens; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Production of specific macrophage-arming factor precedes cytotoxic T lymphocyte activity in vivo during tumor rejection.

Authors:  H F Dullens; R A De Weger; M Van der Maas; P J Den Besten; R J Vandebriel; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Mechanisms of tumour rejection in the murine DBA/2-SL2 concomitant immunity system.

Authors:  D Characiejus; H F Dullens; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Macrophage infiltration in tumors and tumor-surrounding tissue: influence of serotonin and sensitized lymphocytes.

Authors:  G Los; R A De Weger; D T Van den Berg; R Sakkers; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

5.  Antitumor effector mechanism at a distant site in the double grafted tumor system of PSK, a protein-bound polysaccharide preparation.

Authors:  T Ebina; H Kohya
Journal:  Jpn J Cancer Res       Date:  1988-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.